DOSTINEX

LOE Approaching

cabergoline

NDAORALTABLET
Approved
Dec 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6

Mechanism of Action

D2 receptors. Results of in vitro studies demonstrate that cabergoline exerts a direct inhibitory effect on the secretion of prolactin by rat pituitary lactotrophs. Cabergoline decreased serum prolactin levels in reserpinized rats. Receptor-binding studies indicate that cabergoline has low affinity…

Pharmacologic Class:

Ergot Derivative

Clinical Trials (5)

NCT01915303Phase 2Terminated

Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

Started Mar 2014
68 enrolled
Cushings Disease
NCT01270711N/ACompleted

Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)

Started Nov 2010
22,014 enrolled
Parkinson's DiseaseHyperprolactinemia
NCT00376064Phase 4Completed

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Started Mar 2006
20 enrolled
Acromegaly
NCT00242008Phase 3Completed

A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease

Started Dec 2004
Parkinson's Disease
NCT00625547Phase 3Completed

A Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLS

Started Jan 2003
361 enrolled
Restless Legs Syndrome